These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10442345)

  • 1. Rising PSA after local therapy failure: immediate vs deferred treatment.
    Moul JW
    Oncology (Williston Park); 1999 Jul; 13(7):985-90, 993; discussion 993-5, 999. PubMed ID: 10442345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
    Tzou K; Tan WW; Buskirk S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
    Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
    J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rising PSA in nonmetastatic prostate cancer.
    Moul JW; Bañez LL; Freedland SJ
    Oncology (Williston Park); 2007 Nov; 21(12):1436-45; discussion 1449, 1452, 1454. PubMed ID: 18077992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
    Simmons MN; Stephenson AJ; Klein EA
    Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rising Prostate Specific Antigen following treatment with curative intention].
    Jakobsen H; Pedersen KV
    Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
    Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
    Moul JW
    Mol Urol; 2000; 4(3):267-71;discussion 273. PubMed ID: 11062383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen recurrence after definitive therapy.
    Freedland SJ; Moul JW
    J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.